CT-041 is under clinical development by CARsgen Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-041 overview
CARsgen Therapeutics overview
CARsgen Therapeutics (CARsgen) operates as a clinical-stage immune-oncology company focused on developing Chimeric Antigen Receptor T cell therapies for cancer. Its pipeline product includes CAR-GPC3-T for the treatment of late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma; CAR-EGFR targeting Glioblastoma (GBM); CAR-CD19-T against lymphoma and B cell leukemia; CAR-Claudin18.2-T for gastric and pancreatic cancers; and CAR-BCMA-T against multiple myeloma. The company works in strategic partnerships with Shanghai Cancer Institute, Renji Hospital and Changhai Hospital. CARsgen is headquartered in Shanghai, China.
For a complete picture of CT-041’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
